Veronate inhibitex

Current Opinion in Investigational Drugs

Volumn 7, Issue 2, 2006, Pages 172-179

  Kaufman, David ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTASTAPH; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BSYX A110; INH A00021; INH A21; OXACILLIN; PLACEBO; STAPHVAX; UNCLASSIFIED DRUG; VERONATE;

ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; APNEA; BACTEREMIA; BRADYCARDIA; BRAIN HEMORRHAGE; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; DERMATITIS; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; ENDOCARDITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMMUNOTHERAPY; INFECTION PREVENTION; KIDNEY DYSFUNCTION; LICENSING; LUNG DYSPLASIA; NONHUMAN; OBSTRUCTIVE JAUNDICE; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; TACHYPNEA; VERY LOW BIRTH WEIGHT;

ANIMALS; ANTI-INFECTIVE AGENTS; CANDIDA; CANDIDIASIS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 32544454637     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. 321105 Inhibitex and BioResearch Ireland collaborate to discover novel therapeutics to prevent antibiotic-resistant bacterial infections. Inhibitex Inc PRESS RELEASE 1999 April 13
2. 467825 Drug development pipeline; Veronate, SA-IGIV. Inhibitex Inc COMPANY COMMINICATION 2002 October 24
3. 473813 Inhibitex receives FDA Fast Track status for Veronate; enrollment of phase I study completed. Inhibex Inc PRESS RELEASE 2002 December 11
4. 507427 List of all orphan products designations and approvals. WORLD WIDE WEB SITE 2002 October 15 http://www.fda.gov
5. 509343 A phase I, multicenter study of safety and tolerance of a donor-selected staphylococcal immune globulin in very low birth weight infants. Bloom BT, Kueser TJ, Oelberg DJ, Bifano EM, tMiite RD, Schelonka RL, Pearlman SA, Hetherington SV PEDIATR RES 2003 53 4 Pt 2 316a
6. 527858 MSCRAMM - Targeted vaccines and immunotherapy for staphylococcal infection. Rivas JM, Speziale P, Patti JM, Hook M CURR OPIN DRUG DISCOV DEV 2004 7 2 223-227
7. 546938 Inhibitex initiates enrollment in pivotal phase III trial for Veronate. Inhibex Inc PRESS RELEASE 2004 June 30
8. 560181 Inhibitex to add Canadian sites to ongoing phase III clinical trial for Veronate. Inhibex Inc PRESS RELEASE 2004 September 22
9. 569096 INH-A21 contains antibodies specific for the Candida ALS protein family. Liu Y, Brignola L, Vemachio J, Patti JM ICAAC 2004 44 Abs M-1144
10. 591092 Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Reilley S, Wenzel E, Reynolds L, Bennett B, Patti JM, Hetherington S ANTIMICROB AGENTS CHEMOTHER 2005 49 3 959-962
11. 620385 Product candidates. Biosynexus Inc COMPANY WORLD WIDE WEB SITE 2005 August 31
12. 631555 Nabi Biopharmaceuticals announces results of StaphVAX confirmatory phase III clinical trial. Nabi Biopharmaceuticals PRESS RELEASE 2005 November 01
13. 634814 Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W et al PEDIATRICS 2002 110 2 Pt 1 285-291
14. 634822 Annual summary of vital statistics - 2002. Arias E, MacDorman MF, Strobino DM, Guyer B PEDIATRICS 2003 112 6 Pt 1 1215-1230
15. 634825 Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, Tyson JE, Philips JB III, Edwards W, Lucey JF, Catz CS et al PEDIATR INFECT DIS J 1998 17 7 593-598
16. 634831 Pathogen-specific early mortality in very low birth weight infants with late-onset sepsis: A national survey. Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B CLIN INFECT DIS 2005 40 2 218-224
17. 634834 Mortality following blood culture in premature infants: Increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. Benjamin DK, DeLong E, Cotten CM, Garges HP, Steinbach WJ, Clark RH J PERINATOL 2004 24 3 175-180
18. 634837 Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Kaufman D, Fairchild KD CLIN MICROBIOL REV 2004 17 3 638-680
19. 635012 Inhibitex reports completion of enrollment in pivotal phase III clinical trial of Veronate. Inhibitex Inc PRESS RELEASE 2005 November 16
20. 635083 The current role of colony-stimulating factors in prevention and treatment of neonatal sepsis. Banerjea MC, Speer CP SEMIN NEONATOL 2002 7 4 335-349
21. 635084 Topical ointment for preventing infection in preterm infants. Conner JM, Soll RF, Edwards WH COCHRANE DATABASE SYST REV 2004 CD001150
22. 635086 Fluconazole prophylaxis in a neonatal intensive care unit. Healy C, Zaccaria E, Campbell J, Baker C PEDIATR RES 2004 55 395A
23. 635088 Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of < 1000 grams birth weight. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB J PEDIATR 2005 147 2 172-179
24. 635089 Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF J PEDIATR 2005 147 2 162-165
25. 635090 Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. Healy CM, Baker CJ, Zaccaria E, Campbell JR J PEDIATR 2005 147 2 166-171
26. 635096 Reducing Candida infections during neonatal intensive care: Management choices, infection control, and fluconazole prophylaxis. Long SS, Stevenson DK J PEDIATR 2005 147 2 135-141
27. 635098 Fluconazole prophylaxis against fungal colonization and infection in preterm infants. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG N ENGL J MED 2001 345 23 1660-1666
28. 635137 Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB PEDIATRICS 2001 107 2 293-298
29. 635146 Prevention of Gram-positive sepsis in neonates weighing less than 1500 grams. Kacica MA, Horgan MJ, Ochoa L, Sandler R, Lepow ML, Venezia RA J PEDIATR 1994 125 2 253-258
30. 635147 Prevention of central venous catheter-related coagulase-negative staphylococcal sepsis in neonates. Spafford PS, Sinkin RA, Cox C, Reubens L, Powell KR J PEDIATR 1994 125 2 259-263
31. 635151 A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Garland JS, Alex CP, Mueller CD, Otten D, Shivpuri C, Harris MC, Naples M, Pellegrini J, Buck RK, McAuliffe TL, Goldmann DA, Maki DG PEDIATRICS 2001 107 6 1431-1436
32. 635153 Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: An evidence-based review. Laupland KB, Conly JM CLIN INFECT DIS 2003 37 7 933-938
33. 635156 Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: A randomized study. Wertheim HF, Vos MC, Ott A, Voss A, Kluytmans JA, Vandenbroucke-Grauls CM, Meester MH, van Keulen PH, Verbrugh HA ANN INTERN MED 2004 140 6 419-425
34. 635159 Delineation of the functional capacity of human neonatal lymphocytes. Splawski JB, Jelinek DF, Lipsky PE J CLIN INVEST 1991 87 2 545-553
35. 635160 Developmental regulation of the human antibody repertoire. Schroeder HW Jr, Mortari F, Shiokawa S, Kirkham PM, Elgavish RA, Bertrand FE 3rd ANN NY ACAD SCI 1995 764 242-260
36. 635163 Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Ohlssan A, Lacy JB COCHRANE DATABASE SYST REV 2004 CD001239
37. 635165 Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB N ENGL J MED 1992 327 4 213-219
38. 635166 A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, Tyson JE, Philips JB 3rd, Edwards W, Lucey JF N ENGL J MED 1994 330 16 1107-1113
39. 635169 MSCRAMM-mediated adherence of microorganisms to host tissues. Patti JM, Allen BL, McGavin MJ, Hook M ANNU REV MICROBIOL 1994 48 585-617
40. 635170 Microbial adhesins recognizing extracellular matrix macromolecules. Patti JM, Hook M CURR OPIN CELL BIOL 1994 6 5 752-758
41. 635172 Surface protein adhesins of Staphylococcus aureus. Foster TJ, Hook M TRENDS MICROBIOL 1998 6 12 484-488
42. 635176 Immunotherapeutics for nosocomial infections. Patti JM EXPERT OPIN INVESTIG DRUGS 2004 13 6 673-679
43. 635177 Coagulase-negative staphylococcal disease: Emerging therapies for the neonatal and pediatric patient. Weisman LE CURR OPIN INFECT DIS 2004 17 3 237-241
44. 635186 Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants. Capparelli EV, Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD, Schelonka RL, Pearlman SA, Patti J, Hetherington SV ANTIMICROB AGENTS CHEMOTHER 2005 49 10 4121-4127
45. 635187 Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Ohlsson A, Lacy JB COCHRANE DATABASE SYST REV 2004 CD000361
46. 635189 Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Bloom B, Schelonka R, Kueser T, Walker W, Jung E, Kaufman D, Kesler K, Roberson D, Patti J, Hetherington S PEDIATR INFECT DIS J 2005 24 10 858-866
47. 635476 Prevention of experimental Staphylococcus epidermidis (SE) endocarditis (IE) by passive immunotherapy with INH-A00021, a human IgG directed against staphylococcal fibrinogen-binding proteins. Kupferwasser L, Prater B, Wang J, Ruckstuhl MJ, Lee K, Gast D, Adams D, Patti JM, Bayer AS ICAAC 2001 41 Abs G-1715
48. 637774 Inhibitex announces favorable regulatory developments for Veronate. Inhibitex Inc PRESS RELEASE 2005 November 29
49. 638054 A blinded, randomized, multicenter study to assess the safety of an intravenous Staphylococcus aureus immune globulin (human) [Altastaph] in very-low-birth-weight (VLBW) neonates. Benjamin DK Jr, Schelonka R, White RD, Holley P, Bifano EM, Cummings J, LeBlanc M, Kaufman D, White J, Cotton CM PEDIATRIC ACADEMIC SOCIETIES ANNUAL MEETING, Washington, DC, USA 2005 57 Abs 2341
50. 638606 Data safety monitoring board unanimously recommends completion of Veronate pivotal phase III trial as originally designed. Inhibitex Inc PRESS RELEASE 2005 December 05
51. 640411 Marginal increase in cost and excess length of stay associated with nosocomial bloodstream infections in surviving very low birth weight infants. Payne NR, Carpenter JH, Badger GJ, Horbar JD, Rogowaki J PEDIATRICS 2004 114 2 348-355
52. 642210 Nabi Biopharmaceuticals updates progress of its Gram-positive infections portfolio. Nabi Biopharmaceuticals PRESS RELEASE 2005 December 20
53. 642320 Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. McDevitt D, Francois P, Vaudaux P, Foster TJ MOL MICROBIOL 1994 11 2 237-248
54. 642330 The serine-aspartate repeat (Sdr) protein family in Staphylococcus epidermidis. McCrea KW, Hartford O, Davis S, Eidhin DN, Lina G, Speziale P, Foster TJ, Hook M MICROBIOLOGY 2000 146 7 1535-1546
55. 644970 Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: A single-center, 6-year, retrospective cohort study. Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA, Gomirato G PEDIATRICS 2006 117 1 E22-E32